MBX Biosciences unveils 2026 drug milestones at J.P. Morgan Healthcare Conference
MBX Biosciences will present its latest clinical progress and 2026 outlook at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is advancing multiple drug candidates, including treatments for obesity, chronic hypoparathyroidism, and post-bariatric hypoglycemia.
With around $373.7 million in unaudited cash and marketable securities as of December 31, 2025, the firm expects to fund operations into 2029.
The company’s lead candidate, MBX 4291, a GLP-1/GIP co-agonist prodrug, is currently in Phase 1 testing. Data from the 12-week multiple ascending dose study is anticipated in the fourth quarter of 2026.
For chronic hypoparathyroidism, the Phase 2 Avail trial of once-weekly canvuparatide met its primary endpoint, showing high responder rates and good tolerability. Full 12-week results and one-year follow-up data will be shared at a medical conference in the second quarter of 2026. An FDA End-of-Phase 2 meeting is scheduled for the first quarter of 2026, with a Phase 3 confirmatory trial expected to begin in the third quarter. In post-bariatric hypoglycemia, results from the Phase 2a STEADY trial of imapextide—another potential once-weekly treatment—are due in the second quarter of 2026. The company also plans to expand its obesity portfolio in 2026. Two new candidates, an amycretin prodrug and a GLP-1/GIP/GCGR prodrug, are in development, both designed for possible once-monthly dosing.
MBX Biosciences continues to advance its pipeline with key data readouts and regulatory milestones expected throughout 2026. The company’s financial position supports operations into 2029, allowing further development of its obesity, metabolic, and endocrine disorder treatments. Updates will be provided at the upcoming J.P. Morgan Healthcare Conference.
